In pursuit of stability enhancement of a prostate cancer targeting antibody derived from a transgenic animal platform

Venkataramani, S., Ernst, R., Derebe, M.G., et al.

Scientific Reports 2020, vol: 10 doi: 10.1038/s41598-020-66636-z

Abstract

Accelerated timelines necessitate the discovery of fully human antibodies as biotherapeutics using transgenic animals with a notion that such mAbs bypass humanization. A transgenic animal derived mAb (PCa75) targeted against a prostate cancer antigen had several ‘unusual residues’ (rare somatic hypermutations, rSHM, with positional frequency of <1%) that resulted in compromised biophysical properties (Tm = 61 °C and intrinsic stability ΔGu = 24.3 kJ/mol) and a sub-optimal immunogenicity profile. In our quest for quality medicine, we pursued antibody engineering strategies to enhance the stability of PCa75. PCa62, an engineered variant of PCa75, retained function while significantly improving the drug-like attributes of the molecule (Tm = 75 °C and intrinsic stability ΔGu = 63.5 kJ/mol). rSHM is rather prevalent, 18 out the 21 approved transgenic animal-derived antibodies have at least one ‘unusual residue’. Thus, engineering of rSHM remains critical to enhance the stability and minimize immunogenicity risk of biotherapeutics.

View Publication

Read how Prometheus is impacting Dr. Venkataramani's team's work

Topics: Prometheus – nanoDSF,  Publications

 

 

 

Previous
Your guide to efficiently develop antibody-based therapeutics
Your guide to efficiently develop antibody-based therapeutics

How to measure stability, why it's important, and where it belongs in the workflow

Up next
High-throughput feasible screening tool for determining enzyme stabilities against organic solvents directly from crude extracts
High-throughput feasible screening tool for determining enzyme stabilities against organic solvents directly from crude extracts

Looking for the optimal formulation for your biologics candidates?

NanoTemper tools can help

Find out how